Gain Therapeutics (NASDAQ:GANX) Receives “Buy” Rating from HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 349.44% from the stock’s current price.

Several other research firms have also recently weighed in on GANX. Oppenheimer reiterated an “outperform” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a report on Wednesday, August 14th. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a research note on Friday, August 9th.

Gain Therapeutics Stock Down 10.6 %

Shares of Gain Therapeutics stock opened at $1.78 on Tuesday. The company’s 50 day moving average price is $1.26 and its 200-day moving average price is $2.07. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $5.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.84 and a current ratio of 2.84. The stock has a market capitalization of $32.13 million, a price-to-earnings ratio of -1.19 and a beta of 0.35.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). Equities research analysts forecast that Gain Therapeutics will post -1.05 EPS for the current year.

Insider Transactions at Gain Therapeutics

In other news, Chairman Khalid Islam purchased 50,000 shares of Gain Therapeutics stock in a transaction that occurred on Friday, August 9th. The shares were bought at an average cost of $1.00 per share, with a total value of $50,000.00. Following the completion of the purchase, the chairman now directly owns 50,000 shares in the company, valued at $50,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 11.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Hohimer Wealth Management LLC bought a new stake in Gain Therapeutics during the second quarter worth about $422,000. Warberg Asset Management LLC purchased a new position in shares of Gain Therapeutics during the second quarter valued at approximately $66,000. Finally, Renaissance Technologies LLC grew its stake in shares of Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares during the last quarter. 11.97% of the stock is currently owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.